Generic Tasmar Availability
TASMAR (tolcapone - tablet; oral)
Manufacturer: VALEANT PHARMS LLC
Approval date: January 29, 1998
Strength(s): 100MG [RLD]
Has a generic version of Tasmar been approved?
No. There is currently no therapeutically equivalent version of Tasmar available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tasmar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: December 19, 1995
Inventor(s): Bernauer; Karl & Borgulya; Janos & Bruderer; Hans & Da Prada; Mose & Zurcher; Gerhard
Assignee(s): Hoffman-La Roche Inc.
Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adenosylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuronal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure.Patent expiration dates:
- December 19, 2012✓
- December 19, 2012
- Tasmar Consumer Information (Wolters Kluwer)
- Tasmar Consumer Information (Cerner Multum)
- Tasmar Advanced Consumer Information (Micromedex)
- Tasmar AHFS DI Monographs (ASHP)
- Tolcapone Consumer Information (Wolters Kluwer)
- Tolcapone Consumer Information (Cerner Multum)
- Tolcapone Advanced Consumer Information (Micromedex)
- Tolcapone AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|